These injectable medications , including Semaglutide and others in the incretin mimetic family, are initially approved for addressing type 2 diabetes . However, they have seen notable attention for their https://gorillasocialwork.com/story28364954/these-medications-the-glp-1-receptor-agonist-class-what-people-want-to-know